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Synopsis
Stem cell regenerative therapies hold promise for treating diseases across the spectrum of 
medicine. Recent clinical trials have confirmed the safety of stem cell delivery to the heart with 
promising but variable results. While significant progress has been made in the preclinical stages, 
the clinical application of cardiac cell therapy is limited by technical challenges, including 
inability to isolate a pure population of cardiac-specific progenitors capable of robust engraftment 
and regeneration, lack of appropriate pre-clinical animal models, uncertainty about the best mode 
of delivery, paucity of adequate imaging modalities, and lack of knowledge about the fate of 
transplanted cells. The inability of transplanted cells to structurally and functionally integrate into 
the host myocardium may pose arrhythmogenic risk to patients. This is in part dependent on the 
type of cell transplanted, where the expression of gap junctions such as connexin-43 is essential 
not only for electromechanical integration, but has also been found to be protective against 
electrical instability post-transplant. Additionally, certain methods of cell delivery, such as 
intramyocardial injection, carry a higher rate of arrhythmias. Other potential contributors to the 
arrhythmogenicity of cell transplantation include re-entrant pathways due to heterogeneity in 
conduction velocities between graft and host as well as graft automaticity. In this paper, we 
discuss the arrhythmogenic potential of cell delivery to the heart.
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The human heart has limited regenerative capacity and there is an unmet demand for 
improved therapies for cardiovascular disease. Both adult stem cells (ASCs) and human 
pluripotent stem cells (hPSCs) have the potential to facilitate development of cell-based 
therapies. ASCs have been employed in clinical trials1,2, and hPSCs have been used 
extensively to regenerate injured mammalian hearts, including a recent report of non-human 
primates3. However, full clinical translation of stem cell-based therapies has been limited by 
numerous challenges including the proarrhythmic nature of stem cell derived cardiac grafts. 
The potential arrhythmic risk may be attributed to differences in electrophysiological 
maturity4,5,6, gap junction isotypes, cell orientation and wave propagation between graft and 
the host myocardium. In vivo, the normal myocardial architecture has a unique three-
dimensional extracellular matrix, offering cyclic mechanical stress (from rhythmic heart 
beating), electric stimulation, cell-cell signaling and topographical cues among the 
cardiomyocytes (CM). Upon injury, the normal architecture is disrupted and CMs are 
replaced by scar tissue and proliferating fibroblasts, which in turn results in compromise of 
the heart's structural integrity and adverse remodeling. These structural changes cause 
anisotrophy, which provides substrates for reentrant arrhythmias. Additionally, the action 
potential duration prolongation may potentially produce early afterdelpoarizations, or 
delayed afterdepolarizations. Any attempt to introduce exogenous cells for regenerative 
purposes should take into consideration the hostile environment, the lack of normal 
myocardial structure and the potential for the introduction of cells in a microenvironment 
where normal cardiomyocyte fibers are replaced by scar. The electromechanical integration 
of the transplanted cells into such an environment may be a farfetched reality, but warrants 
critical analysis and intense research.
In the following sections, we will discuss candidates for stem cell therapies, the mechanisms 
of stem cell cardiac graft induced arrhythmogenicity and the requirements for successful 
integration and electrophysiological coupling of the hPSC cardiac graft to the damaged 
heart.
Candidates for Cardiac Repair
There are two schools of thought regarding cell therapy for cardiac regeneration: i) delivery 
of cells into the heart with the goal of survival, maturation, and integration of the 
transplanted cells for regeneration and replacement of the scar tissue, and ii) delivery of 
therapeutic cells into the heart, where cells may not survive to physically replace the 
damaged tissue, but will ultimately lead to regeneration via paracrine effect and recruitment 
of endogenous cells to repair the scar. While both scenarios could introduce arrhythmia, 
survival and engraftment of transplanted cells may dangerously serve as a nidus for 
arrhythmias.
Potential cell candidates to replace cardiomyocytes in the injured heart must generate an 
action potential, couple this electrical stimulus to contraction and form the necessary gap 
junctions for action potential propagation and integration with host myocytes7. A variety of 
cell types have been studied as potential candidates for cardiac regeneration (Table 1). 
Properties such as propensity for electromechanical integration, arrhythmogenicity and risk 
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of teratoma formation are important considerations in selecting the appropriate cell. Cell 
sources for cardiac cell therapy include skeletal myoblasts, bone marrow progenitors, 
resident cardiac stem cells, human embryonic stem cell (hESCs) and induced pluripotent 
stem cells (iPSCs)7,8,9. Human ESCs, iPSCs and resident cardiac progenitor cells have all 
been reported to differentiate into cardiomyocytes in both in vivo and in vitro studies, 
whereas bone marrow Mesenchymal Stem Cells (MSCs) and skeletal myoblasts rely on 
transdifferentiation10.
In addition to selecting the appropriate cell candidate for transplantation, other concerns 
include the quantity of transplanted cells needed to achieve a clinically reasonable graft size, 
potential for proliferation in vivo and the degree of cell retention7. Methods for 
transplantation include intracoronary and direct intramyocardial via a surgical or catheter-
based approach11. The degree of cell retention is largely dependent on the method of 
transplantation, whereas cell viability and survival after transplantation also depends on the 
cell type and the microenvironment. Widimsky et al. reported that after intracoronary 
injection of bone marrow cells into large animal models and humans, retention rates ranged 
1.3-5.3% two hours after transplantation11. Various methods of transplantation may also 
directly influence the arrhythmogenicity of stem cell therapy, as discussed in later sections.
Finally, another aspect important for successful hPSC integration is graft alignment. If not 
patterned correctly, engrafted cells have a propensity to integrate randomly into the host 
heart and thereby increasing electric heterogeneity and arrhythmogenic foci. Ultimately, 
applications such as tissue engineering need to be utilized to ensure optimal graft alignment.
Skeletal Myoblasts—Skeletal Myoblasts (SMs) are a reservoir for skeletal muscle cell 
regeneration in cases of muscle injury12,13. A major source of SMs are satellite cells, 
resident muscle stem cells responsible for muscle growth, repair and homeostasis14. The 
potential for in vitro amplification of satellite stem cells and their ability to self-renew make 
SMs a desirable target for cardiac stem cell therapy. There are several features unique to 
skeletal myoblasts. These cells are committed to a myogenic lineage and become functional 
myocytes regardless, or rather in spite of, environmental cues12. Further, SMs continue to 
proliferate in vivo with a high degree of resistance to tissue ischemia, leading to larger graft 
sizes. In early mice studies, grafts were shown to be viable for as long as three months post-
transplantation15.
Skeletal myoblasts were used in some of the first clinical trials for cardiac regeneration. 
Despite modest improvements in left ventricular ejection fraction, the increased incidence of 
sustained ventricular tachycardia in cell-treated patients led to increased concerns regarding 
cardiac cell therapy13,16,17. SMs do not express the gap junctions, connexin-43 (Cx43) in 
particular, necessary for electrical coupling with host cardiomyocytes18–20 discussed in 
more detail below. Roell and colleagues have shown that large grafts, if uncoupled with host 
cardiomyocytes, essentially act as a conduction block and thereby serve as a substrate for 
ventricular arrhythmias20,21. Using lentiviral-mediated transduction with Cx43, one study 
showed that genetically modified SMs had increased electrical stability and decreased 
arrhythmogenicity22. Future research into this approach will undoubtedly provide useful 
information.
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Bone Marrow Progenitors—Bone marrow cells (BMCs) have been used extensively as 
a candidate for cardiac regenerative therapy. Clinical trials using unfractionated BMCs, 
mononuclear bone marrow cells (BM-MNC), BMC-derived hematopoietic progenitors, and 
MSCs have reported the safety of these cells, but the clinical benefit has been debated. 
Several explanations have been suggested, including that endothelial precursors within bone 
marrow expressing CD34 and CD133, hematopoietic lineage markers, induce formation of 
new blood vessels within the infarct bed as well as proliferation of pre-existing 
vasculature23. Bone marrow-derived cells that express CD133 have been hypothesized in 
several studies to be the critical cell type involved to cardiac functional recovery24. One in 
particular found that in patients with refractory critical limb ischemia treated with bone 
marrow cells that include CD133+ cells, there was a strong association with increased 
endothelial proliferation locally and angiogenesis25. Neoangiogenesis within the infarct bed 
is especially important as prior work has shown that post-infarct, the capillary network 
within the heart is unable to keep up with increased myocardial demand due to hypertrophy 
and remodeling, leading to infarct extension and further loss of viable tissue. This is 
mediated by marrow secreted factors such as Vascular Endothelial Growth Factor (VEGF) 
and Macrophage Chemoattractant Protein-1 (MCP-1)26, serving to prevent cell apoptosis, 
reduce collagen deposition and scar formation as well as improve left ventricular function23.
The second explanation involves the plasticity of bone marrow-derived cells where it is 
proposed that these cells may have the potential to generate cardiomyocytes. Although this 
has been reported as a mechanism by which transplanted BMCs exert their beneficial effect, 
scientific data supporting transdifferentiation to cardiomyocytes is lacking. Several 
investigators have shown that in vitro and in small animal models, BMC-derived progenitors 
indeed do give rise new cardiomyocytes in addition to contributing to neoangiogenesis in 
myocardial infarct models23,27,28. Other groups have proposed a third mechanism for 
improved cardiac function, demonstrating fusion of BMCs with somatic cells in in vitro and 
in vivo studies29. These fusion cells phenotypically function like the recipient cell. Fusion of 
bone marrow-derived cells has also been seen with hepatocytes in the liver and neurons in 
the brain. This phenomenon may potentially explain the generation of cardiomyocytes 
observed after BMC transplantation29.
Human clinical trials using bone marrow progenitor cells and MSCs were met with fears 
over arrhythmogenesis given results of prior work with skeletal myoblasts. However 
numerous studies have observed no increase in ventricular arrhythmogenicity in MSC and 
bone marrow progenitor treated patients 30–33. In fact recent studies have suggested a 
protective effect from an arrhythmia perspective after MSC transplantation, with one study 
suggesting reversal of cardiac potassium channel remodeling as a possible mechanism34. 
This may also be the result of poor engraftment, with most cells being cleared or otherwise 
lost from the host heart, thereby eliminating the chance of these cells acting as an 
arrhythmogenic substrate35,36. Furthermore, it has been postulated that paracrine effects of 
the MSCs may have a beneficial effect in suppressing the arrhythmogenic substrate. Perin 
and colleagues demonstrated that endocardial injection of autologous bone marrow 
mononuclear cells in patients with end-stage ischemic heart disease led to improved 
perfusion and myocardial contractility37. Others showed similar results with intracoronary 
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delivery of BM mononuclear cells38, consistent with findings in the TOPCARE-AMI trial 
which showed significant improvement in global left ventricular ejection fraction and 
reduced end-systolic volumes30. While data from the BMC trials have been encouraging, no 
study has yet confirmed presence of functioning cardiomyocytes derived from BMCs that 
have integrated into the host myocardium. Future trials and basic research will shed light on 
this controversial field.
Resident Cardiac Stem Cells—Historically, the heart has been regarded as a terminally 
differentiated organ, incapable of regeneration. Cardiac growth was thought to be due to 
increase in cardiomyocyte size rather than number. However this dogma has been 
challenged by several recent studies. Taking advantage of Carbon-14 dating technology, 
researchers have shown that cardiomyocyte renewal does in fact occur, albeit at a slow rate 
of 1% annually at the age of 25 and decaying over time39. Using a “mosaic analysis with 
double markers” mouse model, a recent study found that post-natal cardiomyocyte 
generation is a rare occurrence and that this capacity is limited to a small population of 
cardiomyocytes40, so called resident cardiac stem cells (CSCs). While some have shown 
increased cardiomyogenesis post-cardiac infarct and injury41, this remains controversial. 
CSCs retain stem-cell like properties including self-renewal and multipotentcy with a 
myocardial-restricted phenotype42. They can give rise to cardiomyocytes, smooth muscle 
and endothelial cells with the ability to replenish the coronary microcirculation in some 
cases43. This small pool of progenitor cells also take part in myocardial homeostasis, serving 
to replenish cardiomyocytes post-injury and participating in the remodeling process43.
Although the existence of resident cardiac stem cells in adult mammalian heart has not been 
entirely characterized, several populations have been well studied. One such population is 
the c-kit+/Lin− population that was first described by Beltrami et al. and were shown to give 
rise to myocytes, smooth muscle, and endothelial cells44. Since then, they have gained the 
intrigue of several groups studying their role in cardiac regeneration. One of the first human 
trials was SCIPIO, a phase I randomized trial of autologous c-kit+ CSCs in ischemic heart 
failure45. CSCs were isolated from the right atrial appendage, expanded in culture and post-
coronary artery bypass grafting, the treatment arm underwent intracoronary CSC infusion. 
Compared with control, CSC-treated patients showed improvements in ejection fraction and 
a reduction in infarct size at four months post-infusion. Despite these promising outcomes, 
challenges such as poor survival and retention of CSCs post-transplantation regardless of 
delivery method have yet to be overcome46.
Another rising source of autologous derived cardiomyocytes is cardiospheres (CSps), a term 
first coined by Messina and colleagues in 2004. CSps are a mixture of various cell types, 
including resident cardiac stem cells, spontaneously differentiated cardiomyocytes, and even 
vascular cells47. These self-assembling multicellular clusters are obtained from post-natal 
biopsy specimens and have properties of adult cardiac stem cells48. Cardiosphere derived 
cells (CDCs) have been used in animal studies and clinically with promising results, 
particularly in the CADUCEUS Trial (CArdiosphere-Derived aUtologous stem CElls to 
reverse ventricUlar dysfunction)49. Although primarily designed as a safety trial, 
preliminary data show that intracoronary infusion of CDCs led to decrease in scar size and 
improved function of infarcted myocardium without a significant difference in rates of 
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ventricular arrhythmia between control and treatment arms. This has led to the Allogeneic 
Heart Stem Cells to Achieve Myocardial Regeneration (ALLSTAR) trial which aims to 
determine the safety and effectiveness of allogeneic CDCs in decreasing infarct size in 
patients with myocardial infarction50.
Human Pluripotent Stem Cells—Human embryonic stem cells (hESCs) and induced 
pluripotent stem cells (iPSCs), collectively known as human pluripotent stem cells (hPSCs) 
have the potential to be an unlimited source for a variety of tissue specific cell types. Human 
PSCs can be efficiently differentiated towards a cardiovascular lineage, hence making them 
an enticing candidate for cell therapy to regenerate the damaged myocardium. Induced 
pluripotent stem cells overcome the ethical and social concerns raised with hESCs. Human 
pluripotent stem cells have the advantage of yielding a variety of phenotypes, including 
atrial, nodal and ventricular cardiomyocytes. Though recent studies have seen major 
improvements in the efficiency of cardiac differentiation51,52, shortcomings persist, 
including teratoma formation with both iPSCs and hESCs and prolonged time to procure and 
derive iPSCs53.
Cardiac cells derived from hPSCs can readily engraft into the injured heart and generate a 
spontaneous action potential3. While this makes hPSCs ideal candidates for cell therapy, it 
also raises legitimate concerns over their arrhythmogenicity. Several studies have reported 
that PSC-derived cardiomyocytes exhibit immature and fetal-like electrical activities which 
would make the electromechanical coupling of these cells with the host cardiomyocytes a 
challenge4–6. Additionally, there still remains a significant challenge in isolating a pure 
population of chamber-specific cardiomyocytes from an in vitro differentiation assay. 
Generally, hPSC differentiation does not yield 100% purity for cardiomyocytes and 
moreover the generated myocytes represent a heterogenous population that includes 
ventricular, atrial and nodal cells. It has been suggested that transplanted hESC-derived 
cardiomyocytes display after-depolarizations due to a low expression of the iK1 channel54 
and also have pacemaking currents independent of the host myocardium55,56. Additionally 
due to their allogenic origin, they are at risk for host immune rejection53, a potential 
mechanism for arrhythmogenicity discussed in more detail below. Finally, as is possible 
with introduction of any cell type, the transplanted cells may modify the substrate with 
ectopic electrical activities such that an arrhythmogenic focus is generated.
While the electromechanical coupling of PSC-derived cardiomyocytes in the heart remains a 
significant concern, the host environment may play an essential role. Ardehali et al. for the 
first time showed structural and functional integration of hESC-derived cardiovascular 
progenitors into human fetal hearts57. Shiba also demonstrated that hESC derived CMs can 
electrically couple in guinea pig models and actually suppress arrhythmias in the injured 
heart, seemingly by forming a ‘conduction bridge’ over the scar tissue58. Fully 
understanding the arrhythmogenicity of hPSC cardiac cell transplants ultimately requires 
additional large animal studies with precise assessment of electrical activities that are 
propagated throughout the grafted cells. It is speculated that the proarrhythmic properties of 
hPSC-derived cardiac cells grafts are due to their immature electrophysiological phenotype 
and may be avoided by the employment of in vitro maturation methods prior to 
transplantation59.
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Electrophysiological Studies and Cell Coupling
The clinical application of stem cells to replenish new myocytes in the heart relies on 
electromechanical coupling of the transplanted cells with the host. Also important is the 
ability of the transplanted cells to generate action potentials and thereby perhaps function as 
biological pacemakers. This automaticity was studied in in vitro models which revealed that 
hESCs exhibit spontaneous electrical activity though with significant rhythmic variation60. 
Automaticity can be studied in vitro using whole-cell voltage clamp and simultaneous patch-
clamp/laser scanning confocal calcium imaging61. Studies have also shown that the coupling 
between excitation and contraction is related to calcium-induced calcium release – that is 
local calcium release from the sarcoplasmic reticulum (‘calcium clock’) and activation of 
voltage gated ion channels60,61. Disruption in either of these mechanisms leads to 
dysrhythmic beating or in some cases, suppression of automaticity altogether. Kehat also 
demonstrated electromechanical coupling in vitro62. Within 24-hours of co-culturing human 
embryonic stem cell-derived cardiomyocytes (hESC-CMs) with neonatal rat ventricular 
myocytes, synchronous mechanical activity was detected. High resolution activation maps 
that characterize impulse initiation and propagation revealed close temporal coupling 
between graft and host. Electrophysiological analysis has also shown that hESC-CMs 
express many of the same ion channels as mature cells61,62.
Electromechanical integration of hESC-CMs into injured hearts is essential to improving 
cardiac function (Figure 1). Several in vivo studies have elegantly demonstrated that 
delivery of hESC-CMs into an injured heart leads to at least partial coupling of the 
transplanted cells with the host cardiomyocytes. One group showed that these cells in fact 
form new force-generating units58. The investigators used genetically modified hESC-CMs 
that encoded a fluorescent calcium sensor such that post-transplantation, epicardial 
fluorescent transients could be correlated with electrocardiogram to demonstrate synchrony 
with host myocardium. Ardehali established that when hESC-derived cardiovascular 
progenitors are transplanted in human fetal hearts, they are able to migrate and couple with 
neighboring host cardiomyocytes, exhibiting synchronous electrical activity57. Others have 
also demonstrated that transplanted hESC-CMs survive and integrate in vivo62. In fact, using 
a pig complete heart block model, Kehat and colleagues showed that the transplanted cells 
displayed automaticity and biological pacing functionality.
For functional integration to occur, the electrical potential generated in one cell must be 
sufficient to propagate through gap junctions and depolarize neighboring cells62. Indeed it is 
the disruption of this structure through loss of desmosomes and gap junctions in ischemic 
disease that leads to arrhythmia in the injured heart63. One gap junction of particular 
importance is connexin-43 (Cx43)20,57,62,63,64. It has been shown that transplantation of 
embryonic cardiomyocytes led to increased electrical stability in the injured heart, 
particularly improved coupling between graft and host and decreased incidence of 
ventricular tachycardia, a property that is dependent on connexin-4320,65. In fact, 
transplantation of skeletal myoblasts that do not express Cx43 showed significant increase in 
the rate of arrhythmias. Similar findings were shown in another study where a hypoxic 
culture environment served to restore connexin-43 in mesenchymal stem cells, thereby 
curbing the incidence of arrhythmias66. Nevertheless, expression of Cx43 is not in itself 
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sufficient to suppress the arrhythmic potential of stem cell transplantation and various other 
mechanisms exist.
In addition to electromechanical coupling and formation of gap junctions, another 
mechanism that may have confounding effects on the induction of arrhythmia is cell fusion. 
Studies have shown that bone marrow derived cells selectively fuse with cells in the brain, 
liver, and heart29,67. In sex mismatch studies with transplanted hESC-derived 
cardiomyocytes to investigate the degree of cell fusion observed, less than 3.8% of 
transplanted cells showed evidence of fusion, suggesting that fusion events are rare and 
perhaps transdifferentiation is the dominant process57. The key question of whether these 
fusions have a role in the formation of new cells or a repair and maintenance function 
remains unanswered.
Mechanisms of Arrhythmogenicity
Various mechanisms have been described for the proarrhythmic potential of stem cell 
transplantation (Figure 2). In part these mechanisms are largely dependent on the type of 
cells transplanted as discussed above.
Re-Entrant Pathways and Automaticity—In a study by Liao et al., the proarrhythmic 
risk of hESCs vs. hESC-CMs was investigated in a mouse model of myocardial infarction 
(MI)68. Through in vitro and in vivo experimental evidence, the authors revealed increased 
arrhythmogenesis in the hESC-CM population, particularly prolongedaction potential 
duration, which led to a higher rate of inducible ventricular tachycardia than the hESC 
group. One explanation is that the relative difference in action potential duration between 
transplanted hESC-CMs and intrinsic ventricular CMs facilitates reentrant excitation. 
Another proposed mechanism is that hESC-CMs can cause abnormal impulse initiations, 
serving as ectopic arrhythmic foci, early afterdepolarization (EAD), or delayed 
afterdepolarization (DAD). The in vivo experiments demonstrated that while 
cardiomyocytes integrate with host myocardium, they exhibit immature electrophysiological 
properties that may lead to less organized gap junctions65. These properties predispose the 
substrate to higher rates of arrhythmia.
The reported degree of electrical instability and arrhythmia rate appears to be quite variable 
in the literature, however. One possible explanation for the conflicting data may be 
differences in heart size and rate of the animal models. Many studies have relied on the 
murine model for in vivo cell transplantation studies. However, considering that the intrinsic 
heart rate in mice is approximately 500-600 beats-per-minute, hPSC-CMs will fail to couple 
with the mouse cardiomyocytes to maintain such an elevated contraction rate. Using a 
macaque model of MI, researchers showed that electrical coupling occurs between graft and 
host myocardium3. All transplanted primates demonstrated electromechanical coupling 
evidenced by epicardial fluorescent calcium transients that were synchronous with host 
electrocardiogram. However hESC-CM transplanted primates showed arrhythmias, 
particularly premature ventricular contractions and ventricular tachycardia3. This was 
especially evident in the first two weeks post-transplantation. The coupling rates seen in this 
large-animal study was higher than seen in experiments by Shiba, where in a guinea-pig MI 
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model, only 60% of transplanted hearts demonstrated electrical coupling58. Interestingly, 
when transplanted into uninjured hearts, there was 100% electromechanical coupling, 
suggesting that graft behavior is more heterogenous in injured heart models58. Additionally, 
hESC-CM transplanted guinea pigs showed the lowest fraction of PVCs and spontaneous 
ventricular tachycardia as well as overall a higher rate of electrical stability in studies 
evaluating inducible arrhythmias with programmed electrical stimulation20,58. This was also 
seen in similar experiments with mice69 and rats70. Possible mechanisms for observed 
arrhythmias include the presence of re-entrant circuits as well as graft automaticity62.
The differences in arrhythmia rate observed in large versus small animals appear to be 
related, at least in part, to variation in heart size and rate3. As mentioned above in murine 
models, graft integration with host myocytes is immature and with slower rates of 
ventricular action potential conduction68. This phenomenon may be accentuated in large 
hearts where larger grafts are used, leading to an even slower rate of action potential 
conduction and predisposing to re-entrant loops3. This may explain why increased 
arrhythmogenicity is seen in larger animal studies rather than with mice and guinea pigs. An 
alternate explanation surrounds the species-specific heart rate. Faster heart rates as seen in 
mice (600beats/min) and guinea pigs (230beats/min) favor native conduction pathways over 
graft automaticity or re-entrant loops3. Conversely, macaques have rates between 
100-130beats/min. This slower rate may have increased susceptibility to graft automaticity 
and ventricular arrhythmias.
Impurities in Stem Cell Differentiation—The process of differentiating human 
embryonic stem cells to cardiomyocytes is an imperfect one. The yield of these protocols is 
never 100%, with isolates often containing non-cardiac derivatives, and may be 
contaminated with residual undifferentiated pluripotent stem cells capable of forming 
teratomas in vivo. One explanation for arrhythmogenicity with stem cell transplantation may 
lie in the impurities of the transplanted graft. This hypothesis was tested using a guinea-pig 
chronic infarct model71. At twenty-eight days post-cardiac cryoinjury, animals were 
transplanted with hESC-CMs, non-cardiac hESC derivatives or vehicle, the latter two 
serving as controls. Interestingly there was no statistically significant difference in 
arrhythmia rate between the three groups outside of the peri-procedural period. All animals 
then underwent electrophysiological studies to assess the electrical stability. Of the three 
groups, guinea pigs transplanted with non-cardiac hESC derivatives showed the highest 
degree of electrical instability with a greater incidence of inducible ventricular tachycardia. 
The hESC-CM and vehicle groups were fairly arrhythmia resistant. This data suggests that 
one possible mechanism for arrhythmogenicity in stem cell transplantation is impurity in the 
cardiomyocyte differentiation process. It is suggested that immunological mechanisms could 
potentially explain why this leads to higher arrhythmia rates71. Transplantation of non-
cardiac derivatives could evoke a stronger and more intense host immune response to the 
graft, leading to increased rejection and thereby increased arrhythmogenicity. However this 
hypothesis was not supported in follow-up immunohistochemical studies71. Several 
investigators have isolated hESC-derived cardiomyocytes or cardiovascular progenitors 
using specific surface markers to circumvent the impurity issue57,72,73. Identification of 
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markers that allow for prospective isolation of hESC-derived cardiovascular cells at 
different stages of development is promising and warrants further investigation.
Confounding Factors—In addition to the mechanisms outlined above, perhaps there are 
confounding factors in the mechanism of arrhythmogenicity in stem cell transplantation that 
are in fact cell-independent74. These may include local injury or edema induced by 
myocardial injection65 as well as variation in transplantation methods. Few head-to-head 
studies exist comparing delivery methods, but one in particular showed that intramyocardial 
injection of bone marrow cells was much more arrhythmogenic, including higher rates of 
ventricular tachycardia, than retrograde intracoronary delivery75. One may postulate that 
injection of cell clusters via the intramyocardial route serves to impede electrical conduction 
in the host myocardium as well as stimulate cytokine release from inflammatory cells, both 
of which may lead to higher rates of arrhythmias. It has been also shown that transplantation 
of mesenchymal stem cells induces nerve sprouting and high sympathetic nerve density76. 
While increased sympathetic innervations could lead to improved contractility and left 
ventricular ejection fraction, it could also result in higher rates of arrhythmia in myocardium 
that is already damaged by ischemia77.
Paracrine Effects
Several studies have evaluated how paracrine effects influence the graft electrical activity. 
Some suggest that secretion of soluble factors such as cytokines, chemokines, and growth 
factors from transplanted cells may lead to beneficial effects. This has come to be known as 
the ‘paracrine hypothesis’53. While further work is needed, potential mechanisms for the 
beneficial effects include the release of cryoprotective molecules that increase native 
cardiomyocyte survival, neovascularization including angiogenesis and arteriogenesis, 
alterations in the extracellular matrix resulting in remodeling that leads to increased scar 
strength and reduced ventricular dilation, improved cardiac contractility, and finally 
recruitment and activation of resident cardiac stem cells78. Some groups have also studied 
how the in vitro environment in which cells are cultured affects their arrhythmic potential. 
Hwang and colleagues investigated the effects of paracrine media (media conditioned by 
growing cells) under hypoxic or normoxic conditions66. Using myocardial infarct models in 
rats, they injected hypoxic paracrine media, normoxic paracrine media, or mesenchymal 
stem cells into the infarct border zone. The hypoxic, but not normoxic, paracrine media was 
found to prevent sudden death in rats by improving conduction in the border zone through 
recovery of gap junctions, reducing the degree of fibrosis, and better modulating calcium 
regulatory ion channels, thereby leading to increased electrical stability.
Conclusion
Research in cardiac regeneration has come a long way. Indeed it has moved from bench to 
bedside with promising results in human studies. There is still much more to learn though, 
particularly how to safely use cell therapy to improve conditions such as congestive heart 
failure and ischemic heart disease while minimizing arrhythmogenicity of cell therapy. 
Further work is needed to improve methods of cell delivery and transplantation. Newer 
delivery systems include cell-seeded patches and scaffold-free cell sheets. Cell coupling and 
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engraftment is also of vital importance to reduce risk of re-entrant pathways and 
automaticity that serve as a nidus for arrhythmia. From cell selection to proper graft 
alignment, finding ways to curb the proarrhythmic risk of stem cell transplantation is an 
essential step towards successful clinical application.
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• Candidates for cardiac cell therapy include autologous sources such as bone 
marrow progenitor cells, skeletal myoblasts and resident cardiac stem cells. 
Human pluripotent stem cells including embryonic stem cells and induced 
pluripotent stem cells are additional candidates with vast differentiation 
potential, although no clinical trial has yet tested their efficacy.
• Cell coupling and engraftment are vital to improved myocardial function.
• Mechanisms for arrhythmia in stem cell transplantation include re-entrant 
rhythms, automaticity that is at least in part dependent on host heart rate, non-
cardiac graft contaminates and non-cellular features involving nerve sprouting 
and increased sympathetic innervation.
• Paracrine effects may serve a protective role.
• The method of stem cell transplantation also contributes to arrhythmogenicity, 
in that intramyocardial injection carries a much higher rate of arrhythmia due to 
disruption of the native architecture of the heart.
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Factors influencing successful graft integration. Post-transplantation, successful graft 
integration with host myocardium is dependent on several factors – a cell population with 
low percentage of non-cardiac derivatives, an efficient delivery method that favors cell 
survival and retention, correct graft alignment and gap junction formation that allows for 
electromechanical coupling.
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Mechanisms of arrhythmogenicity. Proposed mechanisms for the higher rates of arrhythmia 
observed with stem cell transplantation include 1) lack of electromechanical integration; 2) 
transplantation of non-cardiomyocyte (CM) derivatives; 3) local injury and edema; 4) nerve 
sprouting resulting in increased sympathetic tone; 5) route of cell delivery, with 
intramyocardial being more arrhythmogenic than retrograde intracoronary; 6) immunologic 
mechanisms leading to rejection and inflammation; 7) graft automaticity; and 8) candidates 
for transplantation, where expression of gap junctions such as Connexin-43 influence the 
arrhythmogenicity of the graft.
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